Bilal Ergül
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bilal Ergül has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Murat Sarikaya
16 shared publications- Levent Filik
Ankara Research Hospital, Gastroenterology Clinic, Ankara, Turkey
14 shared publications - Zeynal Doğan
Ankara Education and Research Hospital, Department of Gastroenterology, Ankara, Turkey
14 shared publications Erdem Koçak
Department of Gastroenterology, Ankara Education and Research Hospital, Ankara, Turkey
6 shared publicationsLevent Filik
Department of Gastroenterology Ankara Education and Research Hospital Ankara Turkey
6 shared publications- Seyfettin Köklü
Professor of Gastroenterology, Ortadogu 19 Mayis Hospital, Dikmen, Cankaya, Ankara, Turkey
4 shared publications
Latest Publications
- 1 January 2024
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 70 (12/2024) , 2268-2274
Association of Low Serum Maresin-1 Levels with Hepatocellular Carcinoma in Cirrhotic Liver
Background: Maresin-1 (MaR1) is a macrophage-derived antiinflammatory lipid mediator that negatively regulates oxidative and proinflammatory cytokines and also restores integrity in various tissues after inflammation. Non-resolving inflammation is known to have an important role in the pathogenesis of hepatocellular carcinoma (HCC). The aim of the present study was to evaluate the role of MaR1 in pathogenesis and early diagnosis of HCC. Methods: The study was conducted in 102 participants, including 30 volunteers with no hepatic disease, 39 patients with hepatic cirrhosis, and 33 patients with HCC that developed additionally to cirrhosis. Serum MaR1 levels of all participants were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was a significant difference between the circulating MaR1 levels of the three groups. MaR1 level was found to be significantly lower in the HCC group compared to the cirrhotic group (p < 0.001) and in the cirrhotic group compared to the healthy control group (p < 0.001). MaR1 level was independently associated with cirrhosis (vs. controls, OR: 0.995, p = 0.025) and with HCC (vs. controls, OR: 0.962, p = 0.035; and vs. cirrhotic patients, OR: 0.987, p = 0.006). ROC analyses demonstrated that MaR1 levels of < 311.66 had 72.73% sensitivity and 100% specificity for HCC differentiation from controls, while a < 428.08 cutoff had 96.97% sensitivity and 38.46% specificity for differentiation from cirrhotic patients. Conclusions: Serum MaR1 levels were significantly decreased in patients with HCC, compared to those with normal or cirrhotic hepatic tissue. Therefore, MaR1 may possibly be a valuable biomarker in the early diagnosis of HCC and in the differential diagnosis of HCC from cirrhosis.
- 1 January 2024
- Published by Clinical Laboratory Publications in Clinical Laboratory
- Vol. 70 (12/2024) , 2268-2274
Association of Low Serum Maresin-1 Levels with Hepatocellular Carcinoma in Cirrhotic Liver
Background: Maresin-1 (MaR1) is a macrophage-derived antiinflammatory lipid mediator that negatively regulates oxidative and proinflammatory cytokines and also restores integrity in various tissues after inflammation. Non-resolving inflammation is known to have an important role in the pathogenesis of hepatocellular carcinoma (HCC). The aim of the present study was to evaluate the role of MaR1 in pathogenesis and early diagnosis of HCC. Methods: The study was conducted in 102 participants, including 30 volunteers with no hepatic disease, 39 patients with hepatic cirrhosis, and 33 patients with HCC that developed additionally to cirrhosis. Serum MaR1 levels of all participants were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was a significant difference between the circulating MaR1 levels of the three groups. MaR1 level was found to be significantly lower in the HCC group compared to the cirrhotic group (p < 0.001) and in the cirrhotic group compared to the healthy control group (p < 0.001). MaR1 level was independently associated with cirrhosis (vs. controls, OR: 0.995, p = 0.025) and with HCC (vs. controls, OR: 0.962, p = 0.035; and vs. cirrhotic patients, OR: 0.987, p = 0.006). ROC analyses demonstrated that MaR1 levels of < 311.66 had 72.73% sensitivity and 100% specificity for HCC differentiation from controls, while a < 428.08 cutoff had 96.97% sensitivity and 38.46% specificity for differentiation from cirrhotic patients. Conclusions: Serum MaR1 levels were significantly decreased in patients with HCC, compared to those with normal or cirrhotic hepatic tissue. Therefore, MaR1 may possibly be a valuable biomarker in the early diagnosis of HCC and in the differential diagnosis of HCC from cirrhosis.
- Open Access
- 1 April 2019
- Published by AVES YAYINCILIK A.Ş. in Gazi Medical Journal
- Vol. 30 (2) , 125-129
Antioxidative and Immunomodulatory Effects of A-Lipoic Acid in Rat Colitis Model Induced by Acetic Acid
Background/Aim: Benefit of α-Lipoic acid ( ALA) was previously shown in rat-colitis model via suppression of neutrophil accumulation, preservation of endogenous glutathione and inhibition of reactive oxidant generation. Ulcerative colitis is a chronic inflammatory condition of the colon and cytokines (such as TNF-α, IL-1β and TGF-β) are crucial components of these inflammatory pathways. Hence, the present study was undertaken to evaluate the antioxidative and immunomodulatory effects of ALA on experimental colitis model induced by acetic acid in Wistar albino rats. Methods: Mice received either a control diet or ALA-supplemented diet for 14 d. Colitis was induced by acetic acid administration at 7 th day. Mucosal damage and the activation of immune cells and cytokines were determined by macroscopic score, histological score, tissue cytokine levels ( TNF-α, IL-1β and TGF-β). Anti-oxidant effect of ALA was determined by Malondialdehyde, and total antioxidative status. Results: Disease activity Index was significantly higher in colitis group compared to control, ALA and ALA-colitis groups (p<0.001). No significant difference was found between DAI of control, ALA and ALA-colitis groups. The inflammatory mediators, TNF-α and IL-1β, and MDA were elevated in colitis group compared to other groups (p<0.001, p<0.001 respectively). TGF-β and total antioxidative status were significantly lower in colitis group (p<0.001). Conclusion: ALA may possibly have some therapeutic usefulness in the management of ulcerative colitis.
- 1 April 2019
- Published by AVES YAYINCILIK A.Ş. in Gazi Medical Journal
- Vol. 30 (2) , 125-129
Open AccessAntioxidative and Immunomodulatory Effects of A-Lipoic Acid in Rat Colitis Model Induced by Acetic Acid
Background/Aim: Benefit of α-Lipoic acid ( ALA) was previously shown in rat-colitis model via suppression of neutrophil accumulation, preservation of endogenous glutathione and inhibition of reactive oxidant generation. Ulcerative colitis is a chronic inflammatory condition of the colon and cytokines (such as TNF-α, IL-1β and TGF-β) are crucial components of these inflammatory pathways. Hence, the present study was undertaken to evaluate the antioxidative and immunomodulatory effects of ALA on experimental colitis model induced by acetic acid in Wistar albino rats. Methods: Mice received either a control diet or ALA-supplemented diet for 14 d. Colitis was induced by acetic acid administration at 7 th day. Mucosal damage and the activation of immune cells and cytokines were determined by macroscopic score, histological score, tissue cytokine levels ( TNF-α, IL-1β and TGF-β). Anti-oxidant effect of ALA was determined by Malondialdehyde, and total antioxidative status. Results: Disease activity Index was significantly higher in colitis group compared to control, ALA and ALA-colitis groups (p<0.001). No significant difference was found between DAI of control, ALA and ALA-colitis groups. The inflammatory mediators, TNF-α and IL-1β, and MDA were elevated in colitis group compared to other groups (p<0.001, p<0.001 respectively). TGF-β and total antioxidative status were significantly lower in colitis group (p<0.001). Conclusion: ALA may possibly have some therapeutic usefulness in the management of ulcerative colitis.
- 24 April 2018
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 17 (1) , 17-20
Gaitada gizli kan testi pozitifliği nedeni ile kolonoskopi yapılan hastaların kolonoskopik ve patolojik sonuçlarının değerlendirilmesi
Giriş ve Amaç: Kolorektal kanser taramasında gaitada gizli kan testi dışında, fekal immünokimyasal test, fleksible sigmoidoskopi ve kolonoskopi kullanılan diğer yöntemlerdir. Bu çalışmada gaitada gizli kan testi pozitif olması nedeni ile kolonoskopi istenmiş olan hastaların kolonoskopik ve patolojik bulgularını değerlendirmeyi amaçladık. Gereç ve Yöntem: Bu çalışmaya Haziran 2014-Ekim 2016 yılları arasında gaitada gizli kan testi pozitif saptanan ve kolonoskopi yapılması için Ahi Evran Üniversitesi Eğitim ve Araştırma Hastanesi endoskopi ünitesine yönlendirilen hastalar alındı. Yetersiz kolon temizliği, aktif hematokezyası, kolon operasyonu öyküsü, inflamatuvar barsak hastalığı öyküsü veya üst gastrointestinal sistem endoskopisinde kanamaya neden olabilecek lezyonu olan hastalar çalışma dışı bırakıldı. Hastaların yaşları, cinsiyetleri, kolonoskopik bulguları, patoloji sonuçları not edildi. Üç ya da daha fazla polip, 1 cm’den büyük adenomatöz polip, patolojik incelemede villöz komponent içeren ya da yüksek dereceli displazi saptanan hastalar yüksek riskli grup olarak değerlendirildi ve bu kriterlere göre kolon kansertarama programına alındı. Bulgular: Çalışmaya toplam 225 hasta dâhil edildi. Hastaların 111’i (%49.3) erkek, 114’ü (%50.7) kadın, ortalama yaşları 58.52 (24-90), ortalama hemoglobin düzeyi 13.63 (7.2-18) idi. Endoskopik tanıları; normal kolonoskopik bulgular 86 (%38,2), polip 59 (%26,2) , yalnızca perianal hastalık 27 (%12), divertikül 16 (%7,1), kolon kanseri 14 (%6,2), inflamatuvar barsak hastalığı 14 (%6,2), enfeksiyöz kolit 6 (%2,7), anjiodisplazi 3 (%1,3) hasta şeklinde idi. Endoskopik olarak kolon kanseri düşünülen ve polip saptanan 73 (%32,4) hastanın patoloji sonuçları; tübüler adenom 31 (%42,5), adenokarsinom 17 (%23,3), hiperplastik polip 16 (%21,9), tübülovillöz adenom 7 (%9,6), serrated adenom 2 (%2,7) şeklinde değerlendirildi. Kolonoskopik olarak polip saptanan 3 (%5,08) hastanın patolojisinde erken evre karsinom saptandı. Polip saptanan 59 hastanın 30’u (%50,8) yüksek riskli, 29’u (%49,2) düşük riskli olarak bulundu. Sonuç: Gaitada gizli kan testi pozitifliği ile gelen hastaların yaklaşık yarısında kolon patolojisi tespit edilmiştir. Bu test, kolon kanseri ve öncül lezyonlarının tespitinde olduğu gibi, subklinik inflamatuvar barsak hastalığı, kronik kan kaybına yol açan divertikül, anjiodisplazi gibi patolojilerin de tespitinde yardımcı olan ucuz, kolay uygulanabilir bir yöntemdir.
- 24 April 2018
- Published by Turkish Journal of Academic Gastroenterology in Akademik Gastroenteroloji Dergisi
- Vol. 17 (1) , 17-20
Gaitada gizli kan testi pozitifliği nedeni ile kolonoskopi yapılan hastaların kolonoskopik ve patolojik sonuçlarının değerlendirilmesi
Giriş ve Amaç: Kolorektal kanser taramasında gaitada gizli kan testi dışında, fekal immünokimyasal test, fleksible sigmoidoskopi ve kolonoskopi kullanılan diğer yöntemlerdir. Bu çalışmada gaitada gizli kan testi pozitif olması nedeni ile kolonoskopi istenmiş olan hastaların kolonoskopik ve patolojik bulgularını değerlendirmeyi amaçladık. Gereç ve Yöntem: Bu çalışmaya Haziran 2014-Ekim 2016 yılları arasında gaitada gizli kan testi pozitif saptanan ve kolonoskopi yapılması için Ahi Evran Üniversitesi Eğitim ve Araştırma Hastanesi endoskopi ünitesine yönlendirilen hastalar alındı. Yetersiz kolon temizliği, aktif hematokezyası, kolon operasyonu öyküsü, inflamatuvar barsak hastalığı öyküsü veya üst gastrointestinal sistem endoskopisinde kanamaya neden olabilecek lezyonu olan hastalar çalışma dışı bırakıldı. Hastaların yaşları, cinsiyetleri, kolonoskopik bulguları, patoloji sonuçları not edildi. Üç ya da daha fazla polip, 1 cm’den büyük adenomatöz polip, patolojik incelemede villöz komponent içeren ya da yüksek dereceli displazi saptanan hastalar yüksek riskli grup olarak değerlendirildi ve bu kriterlere göre kolon kansertarama programına alındı. Bulgular: Çalışmaya toplam 225 hasta dâhil edildi. Hastaların 111’i (%49.3) erkek, 114’ü (%50.7) kadın, ortalama yaşları 58.52 (24-90), ortalama hemoglobin düzeyi 13.63 (7.2-18) idi. Endoskopik tanıları; normal kolonoskopik bulgular 86 (%38,2), polip 59 (%26,2) , yalnızca perianal hastalık 27 (%12), divertikül 16 (%7,1), kolon kanseri 14 (%6,2), inflamatuvar barsak hastalığı 14 (%6,2), enfeksiyöz kolit 6 (%2,7), anjiodisplazi 3 (%1,3) hasta şeklinde idi. Endoskopik olarak kolon kanseri düşünülen ve polip saptanan 73 (%32,4) hastanın patoloji sonuçları; tübüler adenom 31 (%42,5), adenokarsinom 17 (%23,3), hiperplastik polip 16 (%21,9), tübülovillöz adenom 7 (%9,6), serrated adenom 2 (%2,7) şeklinde değerlendirildi. Kolonoskopik olarak polip saptanan 3 (%5,08) hastanın patolojisinde erken evre karsinom saptandı. Polip saptanan 59 hastanın 30’u (%50,8) yüksek riskli, 29’u (%49,2) düşük riskli olarak bulundu. Sonuç: Gaitada gizli kan testi pozitifliği ile gelen hastaların yaklaşık yarısında kolon patolojisi tespit edilmiştir. Bu test, kolon kanseri ve öncül lezyonlarının tespitinde olduğu gibi, subklinik inflamatuvar barsak hastalığı, kronik kan kaybına yol açan divertikül, anjiodisplazi gibi patolojilerin de tespitinde yardımcı olan ucuz, kolay uygulanabilir bir yöntemdir.
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S504-S505
HBeAg negative chronic hepatitis B patients with HBV-DNA levels between 2,000–20,000IU/ml and normal aminotransferases are really inactive?
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S504-S505
HBeAg negative chronic hepatitis B patients with HBV-DNA levels between 2,000–20,000IU/ml and normal aminotransferases are really inactive?
- 23 November 2017
- Published by Endoscopy Gastrointestinal in Endoskopi Gastrointestinal
- p. 77-79
ERCP’nin nadir bir komplikasyonu: Subkapsüler hematom
- 23 November 2017
- Published by Endoscopy Gastrointestinal in Endoskopi Gastrointestinal
- p. 77-79
ERCP’nin nadir bir komplikasyonu: Subkapsüler hematom
- Open Access
- 1 January 2015
- Published by Wolters Kluwer Health in Saudi Journal of Gastroenterology
- Vol. 21 (1) , 57
Response to ‘Letter to Editor’
- 1 January 2015
- Published by Wolters Kluwer Health in Saudi Journal of Gastroenterology
- Vol. 21 (1) , 57
Open AccessResponse to ‘Letter to Editor’
- 1 November 2014
- Vol. 27 (6) , 1827-35
The protective effect of Echinacea spp. (Echinacea angustifolia and Echinacea purpurea) in a rat colitis model induced by acetic acid.
Ulcerative colitis (UC) is a chronic disease that causes an inflammatory condition in the colon. Several cytokines, including tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β) and transforming growth factor beta (TGF-β) are crucial components of these inflammatory pathways. New therapeutic strategies are needed for improved clinical outcomes in UC and with less adverse effects. That is why alternative therapies such as herbal remedies are increasingly being used with favorable effects in the treatment of UC. Hence, in the present study, we aimed to evaluate the protective effect of Echinacea spp in an experimental rat colitis model induced by acetic acid (AA). Acetic acid was given via a rectal route to induce acute colitis in rats. Rats were placed in four groups: control, Echinacea, Echinacea-colitis and colitis. Tumor necrosis factor alpha, IL-1β and TGF-β levels were measured. Histopathological comparison of the groups was also performed. The disease activity index (DAI) was significantly higher in the colitis group compared to the control, Echinacea and Echinacea-colitis groups (p0.07). The inflammatory mediators IL-1β and TNF-α were significantly elevated in the colitis group compared to the other groups (p<0.007, <0.001 respectively). Therefore, Echinacea spp. may likely have some therapeutic favorable effects in the management of UC.
- 1 November 2014
- Vol. 27 (6) , 1827-35
The protective effect of Echinacea spp. (Echinacea angustifolia and Echinacea purpurea) in a rat colitis model induced by acetic acid.
Ulcerative colitis (UC) is a chronic disease that causes an inflammatory condition in the colon. Several cytokines, including tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β) and transforming growth factor beta (TGF-β) are crucial components of these inflammatory pathways. New therapeutic strategies are needed for improved clinical outcomes in UC and with less adverse effects. That is why alternative therapies such as herbal remedies are increasingly being used with favorable effects in the treatment of UC. Hence, in the present study, we aimed to evaluate the protective effect of Echinacea spp in an experimental rat colitis model induced by acetic acid (AA). Acetic acid was given via a rectal route to induce acute colitis in rats. Rats were placed in four groups: control, Echinacea, Echinacea-colitis and colitis. Tumor necrosis factor alpha, IL-1β and TGF-β levels were measured. Histopathological comparison of the groups was also performed. The disease activity index (DAI) was significantly higher in the colitis group compared to the control, Echinacea and Echinacea-colitis groups (p0.07). The inflammatory mediators IL-1β and TNF-α were significantly elevated in the colitis group compared to the other groups (p<0.007, <0.001 respectively). Therefore, Echinacea spp. may likely have some therapeutic favorable effects in the management of UC.
- 1 July 2014
- Published by Wolters Kluwer Health in Gastroenterology Nursing
- Vol. 37 (4) , 304-305
PROCTALGIA DUE TO TELAPREVIR
- 1 July 2014
- Published by Wolters Kluwer Health in Gastroenterology Nursing
- Vol. 37 (4) , 304-305
PROCTALGIA DUE TO TELAPREVIR
- 1 June 2014
- Vol. 77 (2) , 235-9
Helicobacter pylori eradication reduces microalbuminuria in type-2 diabetic patients: a prospective study.
To evaluate the effect of Helicobacter Pylori (H. pylori) eradication on microalbuminuria in type 2 diabetic patients. Consecutive patients with dyspepsia, type 2 diabetes mellitus and microalbuminuria were recruited. Upper gastrointestinal endoscopy and rapid urease test (H. pylori fast) were performed for detecting H. pylori infection. Patients with H. pylori infection were given triple treatment. Urea breath tests were performed for all patients after eradication treatment. According to the eradication status, patients were divided into two groups, as H. pylori negative, group 1 (successful eradication group) and H. pylori positive, group 2 (unsuccessful eradication group). Twenty-four hour urine was also collected from all patients at baseline and after H. pylori eradication treatment. A total of 69 patients were included in the study. There were no significant differences between groups for anthropometric measurements and laboratory tests at baseline (p > 0.05). An expected significant difference was found for microlabuminuria and fasting glucose between the two groups. Microalbuminuria and fasting glucose levels were signicantly reduced in the H. pylori negative group compared with the H. pylori positive group after eradication treatment (p < 0.05). Although there was no significant decline in HbA1c levels in the H. pylori negative group, there were relatively lower HbA1c levels compared with baseline for both groups. The rate of attaining normoalbuminuria after eradication was significantly higher in group 1 compared to group 2 (p < 0.05). H. Pylori eradication was found to have a favorable effect on reducing microalbuminuria in diabetic patients.
- 1 June 2014
- Vol. 77 (2) , 235-9
Helicobacter pylori eradication reduces microalbuminuria in type-2 diabetic patients: a prospective study.
To evaluate the effect of Helicobacter Pylori (H. pylori) eradication on microalbuminuria in type 2 diabetic patients. Consecutive patients with dyspepsia, type 2 diabetes mellitus and microalbuminuria were recruited. Upper gastrointestinal endoscopy and rapid urease test (H. pylori fast) were performed for detecting H. pylori infection. Patients with H. pylori infection were given triple treatment. Urea breath tests were performed for all patients after eradication treatment. According to the eradication status, patients were divided into two groups, as H. pylori negative, group 1 (successful eradication group) and H. pylori positive, group 2 (unsuccessful eradication group). Twenty-four hour urine was also collected from all patients at baseline and after H. pylori eradication treatment. A total of 69 patients were included in the study. There were no significant differences between groups for anthropometric measurements and laboratory tests at baseline (p > 0.05). An expected significant difference was found for microlabuminuria and fasting glucose between the two groups. Microalbuminuria and fasting glucose levels were signicantly reduced in the H. pylori negative group compared with the H. pylori positive group after eradication treatment (p < 0.05). Although there was no significant decline in HbA1c levels in the H. pylori negative group, there were relatively lower HbA1c levels compared with baseline for both groups. The rate of attaining normoalbuminuria after eradication was significantly higher in group 1 compared to group 2 (p < 0.05). H. Pylori eradication was found to have a favorable effect on reducing microalbuminuria in diabetic patients.